Roche Diagnostics will build a $550 million expansion to produce continuous glucose monitors at an Indianapolis facility. Roche will use the site to make its Accu-Chek Smartguide devices, which launched last year in Europe as the company’s first continuous glucose monitoring device.

The company will also build a new $700 million factory in Holly Springs, North Carolina. The facility, which is expected to create at least 400 jobs, will produce Roche’s future portfolio of obesity medicines. It will be operated by Roche subsidiary Genentech. 

“Our goal is to initiate production within three years, followed by preparing for future generations of that CGM solution,” Richeal Cline, head of global operations for Roche Diagnostics, said in a Monday press conference. 

The Indianapolis site is Roche Diagnostics’ North American headquarters. It houses research and development, laboratories, manufacturing and other functions, and produces Roche’s Accu-Chek diabetes test strips. The facility is one of two global distribution hubs for the company.

Roche will refurbish an existing building for the manufacturing space and may construct new buildings to meet future demand, Cline said.

The company expects the expansion to create 650 jobs. Roche will receive a 10-year property tax abatement from the city of Indianapolis and about $20 million in tax credits from the state of Indiana, Roche Diagnostics North America CEO Brad Moore said. 

During the event, Roche did not comment directly on whether the expansion is being built in response to President Donald Trump’s tariffs. Last month, the company said it would invest $50 billion in the U.S. over the next five years.

“The expansion helps expand access to U.S. patients here,” Cline said, adding that the Indianapolis facility “provides both capacity growth and resilience of our global manufacturing network.”

Kate Magill contributed to this report.